Bio-Path Holdings Company Profile (NASDAQ:BPTH)

About Bio-Path Holdings (NASDAQ:BPTH)

Bio-Path Holdings logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BPTH
  • CUSIP: N/A
  • Web: www.biopathholdings.com
Capitalization:
  • Market Cap: $39.39 million
  • Outstanding Shares: 95,645,000
Average Prices:
  • 50 Day Moving Avg: $0.62
  • 200 Day Moving Avg: $0.93
  • 52 Week Range: $0.40 - $2.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.59
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $13,000.00
  • Price / Sales: 3,029.74
  • Book Value: $0.09 per share
  • Price / Book: 4.84
Profitability:
  • EBIDTA: ($8,380,000.00)
  • Return on Equity: -81.94%
  • Return on Assets: -68.25%
Debt:
  • Current Ratio: 14.42%
  • Quick Ratio: 14.42%
Misc:
  • Average Volume: 169,761 shs.
  • Beta: 2.64
  • Short Ratio: 24.9
 

Frequently Asked Questions for Bio-Path Holdings (NASDAQ:BPTH)

What is Bio-Path Holdings' stock symbol?

Bio-Path Holdings trades on the NASDAQ under the ticker symbol "BPTH."

How were Bio-Path Holdings' earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) posted its earnings results on Thursday, May, 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. View Bio-Path Holdings' Earnings History.

Where is Bio-Path Holdings' stock going? Where will Bio-Path Holdings' stock price be in 2017?

3 analysts have issued 1 year target prices for Bio-Path Holdings' shares. Their predictions range from $2.00 to $5.00. On average, they anticipate Bio-Path Holdings' share price to reach $4.00 in the next year. View Analyst Ratings for Bio-Path Holdings.

What are analysts saying about Bio-Path Holdings stock?

Here are some recent quotes from research analysts about Bio-Path Holdings stock:

  • 1. According to Zacks Investment Research, "BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. " (3/20/2017)
  • 2. Maxim Group analysts commented, "Bio-Path presented BP1001 (Liposomal Grb2 Antisense) data as a poster presentation titled Phase I Study of BP1001 (Liposomal Grb2 Antisense) in Patients with Hematologic Malignancies" at ASCO. The data included results from the Phase I study of BP1001 for the treatment of acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), and safety data from the Phase II study of BP1001 in combination with low-dose cytarabine (LDAC) for advanced AML. The poster was presented by Dr." (6/6/2016)

Who are some of Bio-Path Holdings' key competitors?

Who owns Bio-Path Holdings stock?

Bio-Path Holdings' stock is owned by many different of retail and institutional investors. Top institutional shareholders include University of Texas Investment Managment Co. (4.01%), Vanguard Group Inc. (3.05%), HighTower Advisors LLC (1.32%), Raymond James Financial Services Advisors Inc. (0.81%), Geode Capital Management LLC (0.72%) and Sabby Management LLC (0.72%). View Institutional Ownership Trends for Bio-Path Holdings.

Who sold Bio-Path Holdings stock? Who is selling Bio-Path Holdings stock?

Bio-Path Holdings' stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC. View Insider Buying and Selling for Bio-Path Holdings.

Who bought Bio-Path Holdings stock? Who is buying Bio-Path Holdings stock?

Bio-Path Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC, HighTower Advisors LLC, Sabby Management LLC, Vanguard Group Inc., Geode Capital Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Bio-Path Holdings.

How do I buy Bio-Path Holdings stock?

Shares of Bio-Path Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bio-Path Holdings stock cost?

One share of Bio-Path Holdings stock can currently be purchased for approximately $0.41.

Analyst Ratings

Consensus Ratings for Bio-Path Holdings (NASDAQ:BPTH) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (871.35% upside)

Analysts' Ratings History for Bio-Path Holdings (NASDAQ:BPTH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017HC WainwrightSet Price TargetBuy$5.00MediumView Rating Details
4/5/2017Maxim GroupSet Price TargetBuy$2.00HighView Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Bio-Path Holdings (NASDAQ:BPTH)
Earnings by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Earnings History by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.02)($0.01)ViewN/AView Earnings Details
3/15/201712/31/2016($0.03)($0.01)$0.01 millionViewListenView Earnings Details
11/9/2016Q316($0.02)($0.02)$2.50 millionViewListenView Earnings Details
8/9/2016Q2($0.02)($0.02)ViewN/AView Earnings Details
5/11/2016Q1($0.01)($0.02)$2.33 millionViewListenView Earnings Details
3/16/2016Q4($0.01)($0.02)$1.46 millionViewN/AView Earnings Details
11/10/2015Q315($0.02)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015Q4 2014$0.01($0.02)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.01)($0.01)ViewN/AView Earnings Details
8/18/2014Q214($0.01)($0.01)ViewN/AView Earnings Details
4/2/2014$0.01$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Path Holdings (NASDAQ:BPTH)
Current Year EPS Consensus Estimate: $-0.0700 EPS
Next Year EPS Consensus Estimate: $-0.0200 EPS

Dividends

Dividend History for Bio-Path Holdings (NASDAQ:BPTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Path Holdings (NASDAQ:BPTH)
Insider Ownership Percentage: 12.54%
Institutional Ownership Percentage: 21.00%
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Institutional Ownership by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Insider Trades by Quarter for Bio-Path Holdings (NASDAQ:BPTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Path Holdings (NASDAQ:BPTH)
Latest Headlines for Bio-Path Holdings (NASDAQ:BPTH)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Anticipate Bio-Path Holdings Inc (BPTH) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 13 at 12:02 AM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 11:48 AM
seekingalpha.com logoBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:36 PM
finance.yahoo.com logoBio-Path Holdings Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 4:36 PM
finance.yahoo.com logoBio-Path reports 1Q loss
finance.yahoo.com - May 11 at 4:36 PM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:16 AM
finance.yahoo.com logoBio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017
finance.yahoo.com - May 4 at 4:07 PM
americanbankingnews.com logoPositive Media Coverage Likely to Affect Bio-Path Holdings (BPTH) Stock Price
www.americanbankingnews.com - May 4 at 12:36 AM
americanbankingnews.com logoBio-Path Holdings (BPTH) Earns Daily Media Sentiment Score of 0.13
www.americanbankingnews.com - April 27 at 8:08 PM
americanbankingnews.com logoBio-Path Holdings (BPTH) Receives Daily Coverage Optimism Rating of 0.57
www.americanbankingnews.com - April 21 at 8:47 AM
finance.yahoo.com logoBio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher - Yahoo Finance
finance.yahoo.com - April 19 at 1:11 PM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Short Interest Up 2.3% in March
www.americanbankingnews.com - April 19 at 7:14 AM
americanbankingnews.com logoBio-Path Holdings (BPTH) Getting Very Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 18 at 8:56 AM
finance.yahoo.com logoBio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development
finance.yahoo.com - April 17 at 12:25 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Extremely Likely to Impact Bio-Path Holdings (BPTH) Stock Price
www.americanbankingnews.com - April 15 at 10:29 AM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 7 at 10:44 PM
finance.yahoo.com logoBio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma
finance.yahoo.com - April 7 at 8:40 AM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Given a $2.00 Price Target at Maxim Group
www.americanbankingnews.com - April 5 at 6:45 PM
seekingalpha.com logoBio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:49 AM
americanbankingnews.com logoHC Wainwright Reiterates $5.00 Price Target for Bio-Path Holdings Inc (BPTH)
www.americanbankingnews.com - March 22 at 9:11 AM
americanbankingnews.com logoZacks Investment Research Upgrades Bio-Path Holdings Inc (BPTH) to "Buy"
www.americanbankingnews.com - March 20 at 9:49 PM
americanbankingnews.com logoBio-Path Holdings Inc (BPTH) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 16 at 10:43 AM
biz.yahoo.com logoBio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 15 at 9:21 PM
us.rd.yahoo.com logoBio-Path Holdings Reports Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 4:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 4:20 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
us.rd.yahoo.com - March 15 at 4:20 PM
finance.yahoo.com logoBio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference
finance.yahoo.com - March 14 at 9:18 AM
us.rd.yahoo.com logoBio-Path Holdings to Present Data at the 2017 AACR Annual Meeting
us.rd.yahoo.com - March 10 at 4:57 PM
finance.yahoo.com logoBio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017
finance.yahoo.com - March 9 at 4:36 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - March 8 at 4:46 PM
finance.yahoo.com logoBio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board
finance.yahoo.com - February 21 at 12:18 PM
globenewswire.com logoBio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 9 at 9:14 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
biz.yahoo.com - December 16 at 4:21 PM
streetinsider.com logoBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016
www.streetinsider.com - December 7 at 2:22 AM
us.rd.yahoo.com logoBio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting
us.rd.yahoo.com - December 6 at 4:18 PM
us.rd.yahoo.com logo7:01 am Bio-Path reviews BP1001 data as a treatment for chronic myelogenous leukemia at ASH 2016; results demonstrate BP1001 decreased the proliferation of Gleevec (imatinib)-resistant CML cells in a dose-dependent manner
us.rd.yahoo.com - December 6 at 4:18 PM
biz.yahoo.com logoBIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - December 6 at 4:18 PM
streetinsider.com logoBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016 - StreetInsider.com
www.streetinsider.com - December 6 at 12:14 PM
finance.yahoo.com logoBIO-PATH HOLDINGS INC Financials
finance.yahoo.com - November 17 at 1:51 PM

Social

Chart

Bio-Path Holdings (BPTH) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff